Bank of America Corp DE Acquires 2,212,208 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Bank of America significantly increased its Edwards Lifesciences stake by 132.4%, purchasing 2.21 million additional shares to own 3.88 million shares worth approximately $311 million, or 0.67% of the company.
• Analyst sentiment is positive, with 17 Buy ratings and six Holds producing a “Moderate Buy” consensus and an average price target of $100.27, above the reported share price of $86.17.
• Edwards exceeded quarterly expectations, reporting $0.78 in adjusted EPS versus $0.74 expected and $1.74 billion in revenue versus $1.70 billion estimated; revenue rose 13.6% year over year.

Bank of America Corp DE increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 132.4% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 3,883,419 shares of the medical research company's stock after purchasing an additional 2,212,208 shares during the period. Bank of America Corp DE owned approximately 0.67% of Edwards Lifesciences worth $310,984,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC bought a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $266,000. NewEdge Advisors LLC increased its position in Edwards Lifesciences by 8.1% during the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company's stock worth $2,787,000 after acquiring an additional 2,665 shares during the period. Sei Investments Co. increased its position in Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company's stock worth $32,285,000 after acquiring an additional 58,988 shares during the period. Squarepoint Ops LLC raised its stake in Edwards Lifesciences by 277.7% during the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company's stock valued at $5,417,000 after purchasing an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina raised its stake in Edwards Lifesciences by 0.4% during the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company's stock valued at $21,028,000 after purchasing an additional 1,065 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on EW. BTIG Research increased their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a "buy" rating in a report on Tuesday, June 30th. Leerink Partners upgraded shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $87.00 to $101.00 in a report on Friday, July 24th. Robert W. Baird upped their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a "neutral" rating in a research report on Friday, April 24th. Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Finally, JPMorgan Chase & Co. lifted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a research report on Friday, July 24th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $100.27.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 620 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $81.14, for a total value of $50,306.80. Following the transaction, the vice president directly owned 40,411 shares in the company, valued at approximately $3,278,948.54. This trade represents a 1.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company's stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 43,539 shares of company stock worth $3,685,364. Insiders own 0.31% of the company's stock.

Edwards Lifesciences Trading Up 0.1%

Shares of NYSE EW opened at $86.17 on Monday. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The company has a market cap of $49.62 billion, a PE ratio of 49.52, a P/E/G ratio of 2.16 and a beta of 0.85. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average of $87.91 and a two-hundred day moving average of $83.90.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. Edwards Lifesciences's quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.